NASDAQ:MCURMacrocure Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Macrocure Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.51 0.00 (0.00 %) (As of 01/31/2017) Add Share Today's Range$1.51Now: $1.51▼$1.5150-Day Range N/A52-Week Range$0.75Now: $1.51▼$3.20VolumeN/AAverage Volume98,746 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Leap Therapeutics Ltd, formerly Macrocure Ltd, is a biotechnology company. The Company is focused on developing, manufacturing and commercializing cell therapy products to address unmet needs for the treatment of chronic wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Its product candidate, CureXcell, is a combination of living human white blood cells that have been activated to facilitate the healing process and stimulate wound closure. CureXcell is in Phase III. Its CureXcell addresses each phase of healing in the impaired wound, including the production of growth factors and other biochemical factors involved in fibroblast activation, cell migration and extracellular matrix production, stimulating the body's natural healing process. Its delivery method of direct superficial injection into the chronic wound allows the precise delivery of the cells into the defective wound tissue where they can be effective.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Macrocure. Previous Next 2.4 Community Rank Outperform VotesMacrocure has received 107 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMacrocure has received 114 “underperform” votes. (Add your “underperform” vote.)Community SentimentMacrocure has received 51.58% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Macrocure and other stocks. Vote “Outperform” if you believe MCUR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MCUR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMacrocure does not currently pay a dividend.Dividend GrowthMacrocure does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Macrocure insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 2.83% of the stock of Macrocure is held by institutions. Previous Next 0.0 Earnings and Valuation Previous Next Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.48 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:MCUR Previous Symbol CUSIPN/A CIK1606012 Webwww.macrocure.com Phone+972-3-9235556Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Receive MCUR News and Ratings via Email Sign-up to receive the latest news and ratings for MCUR and its competitors with MarketBeat's FREE daily newsletter. Macrocure (NASDAQ:MCUR) Frequently Asked Questions How were Macrocure's earnings last quarter? Macrocure Ltd (NASDAQ:MCUR) released its earnings results on Tuesday, November, 17th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.36) by $0.04. View Macrocure's earnings history. Has Macrocure been receiving favorable news coverage? Media stories about MCUR stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Macrocure earned a coverage optimism score of -4.8 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutMacrocure. What other stocks do shareholders of Macrocure own? Based on aggregate information from My MarketBeat watchlists, some companies that other Macrocure investors own include LinnCo (LNCOQ), California Resources (CRC), Great Basin Scientific (GBSN), BreitBurn Energy Partners (BBEPQ), VelocityShares Daily 2x VIX Short Term ETN (TVIX), Ultra Petroleum (UPLMQ), U.S. Energy (USEG), SandRidge Energy (SD), Alphatec (ATEC) and Penn Virginia (PVAHQ). What is Macrocure's stock symbol? Macrocure trades on the NASDAQ under the ticker symbol "MCUR." What is Macrocure's stock price today? One share of MCUR stock can currently be purchased for approximately $1.51. What is Macrocure's official website? The official website for Macrocure is www.macrocure.com. How can I contact Macrocure? Macrocure's mailing address is 25 Sivim Street, PETAH TIKVA, 4959383, Israel. The biotechnology company can be reached via phone at +972-3-9235556. This page was last updated on 5/26/2020 by MarketBeat.com Staff
